Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Clinical Lymphoma, Myeloma & Leukemia|September 17, 2025
Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World ExperienceAnas Zayad, Gray Magee, Razan Mansour, et al.
European Journal of Haematology|January 16, 2026
Comparative Efficacy of Daratumumab Based Regimens in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter StudyRazan Mansour, Kimberly M Green, Chandler Graf, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma and Renal ImpairmentAlma Habib, Nausheen Ahmed, Abdullah Mohammad Khan, et al.
Nature Cancer|August 26, 2024
Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trialShambavi Richard, Alexander M Lesokhin, Barry Paul, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2025
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 InstitutesCindy Varga, Myra Robinson, Vikas Gupta, et al.
European Journal of Haematology|June 13, 2023
Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myelomaShebli Atrash, Myra Robinson, Alankrita Taneja, et al.
Future Oncology (London, England)|February 13, 2023
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myelomaBarry Paul, Michaela Liedtke, Jack Khouri, et al.
British Journal of Haematology|April 15, 2025
Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world dataNoa Biran, Binod Dhakal, Ruben Niesvizky, et al.
Cancers|November 13, 2025
Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed IntervalsJordan Snyder, Shebli Atrash, Barry Paul, et al.
Ejhaem|June 9, 2025
Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple MyelomaBarry Paul, Jiri Minarik, Francesca Cottini, et al.
Pageof 5